预约演示

更新于：2024-12-05

Farletuzumab Ecteribulin

更新于：2024-12-05

概要

概要

基本信息

药物类型

ADC

别名

Eribulin/farletuzumab antibody drug conjugate、Farletuzumab/eribulin ADC、FZEC

+ [2]

靶点

FOLR1 x Tubulin

作用机制

FOLR1拮抗剂(叶酸受体α拮抗剂)、微管蛋白抑制剂

治疗领域

肿瘤内分泌与代谢疾病泌尿生殖系统疾病+ [2]

在研适应症

非在研适应症

原研机构

在研机构

Bristol Myers Squibb Co.

Eisai Co., Ltd.

非在研机构

中美上海施贵宝制药有限公司

Morphotek, Inc.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 4703059H

来源: *****

Sequence Code 4703062L

来源: *****

关联

项与 Farletuzumab Ecteribulin 相关的临床试验

NCT05613088

/ Active, not recruiting临床2期

A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.

开始日期2023-02-01

申办/合作机构

Bristol Myers Squibb Co.

[+1]

NCT05577715

/ Terminated临床2期

A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies

The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.

开始日期2022-11-14

申办/合作机构

Bristol Myers Squibb Co.

[+1]

NCT04300556

/ Recruiting临床1/2期

A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types

The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer [OC], endometrial cancer [EC], non-small cell lung carcinoma [NSCLC], triple-negative breast cancer [TNBC]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzumab ecteribulin (MORAb-202) in participants with OC and EC at selected doses and to further evaluate the safety and tolerability of farletuzumab ecteribulin (MORAb-202) and (3) dose-optimization part. (divided in two parts: Part A [OC and EC participants] and Part B [EC only]): Part A: to evaluate other farletuzumab ecteribulin (MORAb-202) treatment regimens for safety, tolerability and preliminary efficacy in participants with OC and EC; to evaluate the use of the addition of short course of oral corticosteroids following every dose of farletuzumab ecteribulin (MORAb-202) administered every 21 days, as mitigation strategy for interstitial lung disease (ILD); and to select treatment regimens with farletuzumab ecteribulin (MORAb-202) for further evaluation in Part B. Part B: to further evaluate the safety, tolerability and preliminary efficacy of 2 treatment regimens with farletuzumab ecteribulin (MORAb-202) in participants with advanced EC and to determine the recommended treatment regimen for further development of farletuzumab ecteribulin (MORAb-202).

开始日期2020-08-06

申办/合作机构

Eisai, Inc.

[+1]

100 项与 Farletuzumab Ecteribulin 相关的临床结果

登录后查看更多信息

100 项与 Farletuzumab Ecteribulin 相关的转化医学

登录后查看更多信息

100 项与 Farletuzumab Ecteribulin 相关的专利（医药）

登录后查看更多信息

项与 Farletuzumab Ecteribulin 相关的文献（医药）

2024-11-01·Cancer Medicine

The Efficacy and Safety of Folate Receptor α‐Targeted Antibody‐Drug Conjugate Therapy in Patients With High‐Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta‐Analysis

Review

作者: Lim, Myong Cheol ; Kim, Eun Taeg ; Kim, Ji Hyun ; Park, Eun Young ; Park, Han Song ; Park, Sang‐Yoon ; Song, In Hye

ABSTRACT:

Background:

Antibody‐drug conjugates (ADC) have emerged as a highly promising systemic option in the treatment of recurrent ovarian cancer. The present study aimed to evaluate the treatment efficacy of folate receptor α (FRα)‐targeting ADCs, associated treatment‐related adverse events (TRAEs), and their impact on treatment safety.

Methods:

We conducted an electronic search to identify prospective trials of single‐agent ADCs targeting FRα and those combined with chemotherapy in recurrent ovarian cancer. Information regarding the objective response rate (ORR) and TRAEs was collectively analyzed, and differences in subgroups based on FRα receptor expression levels were investigated. The protocol was registered with PROSPERO (CRD42023491151).

Results:

Ten studies with a total of 940 patients (859 treated with Mirvetuximab soravtansine‐gynx (MIRV)), 45 with Farletuzumab Ecteribulin (MORAb‐202), and 36 with Luveltamab Tazevibulin (STRO‐002) were included in this meta‐analysis. Based on the pooled data, the ORR of the entire cohort was 37% (95% CI: 0.30–0.43), while that of the high‐FRα expression group was 34% (95% CI: 0.26–0.42). The incidence of grade ≥ 3 adverse events was 27% (95% CI: 0.19–0.36).

Conclusion:

FRα‐targeting ADCs, including MIRV, demonstrated definite efficacy and good safety as novel choices for second‐line and beyond treatment of advanced or recurrent ovarian cancer. Patients with high FRα expression showed ORR and PFS benefits similar to those in the overall cohort.

2021-07-15·Clinical cancer research : an official journal of the American Association for Cancer Research1区 · 医学

First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors

1区 · 医学

Article

作者: Shimizu, Toshio ; Koyama, Takafumi ; Furuuchi, Keiji ; Yamamoto, Noboru ; Fujiwara, Yutaka ; Miura, Takuma ; Tamura, Kenji ; Yonemori, Kan ; Ikezawa, Hiroki ; Shimomura, Akihiko ; Sato, Jun ; Nomoto, Maiko ; Nakajima, Ryo

Abstract:

Purpose::

MORAb-202, an antibody–drug conjugate containing farletuzumab and eribulin with a cathepsin-B cleavable linker, targets folate receptor α (FRα)–expressing tumor cells. The primary objective of this first-in-human study was to evaluate the safety and tolerability of MORAb-202 in patients with solid tumors.

Patients and Methods::

Patients ≥20 years with adequate organ function and FRα-positive solid tumors who failed to respond to standard therapy were eligible. Patients received MORAb-202 intravenously at doses of 0.3 to 1.2 mg/kg once every three weeks. Endpoints included dose-limiting toxicities, safety, tumor responses, pharmacokinetics, and pharmacodynamics. Trial registration number: NCT03386942 (ClinicalTrials.gov).

Results::

Between November 28, 2017 and June 4, 2019, 22 patients (median age, 58.0 years) with advanced solid tumors were enrolled. Treatment-emergent adverse events occurred in 21 (95%) patients, with leukopenia and neutropenia in 10 (45%) patients each. One patient (0.9 mg/kg cohort) experienced two grade 3 dose-limiting toxicities: serum alanine aminotransferase and γ-glutamyl transferase increases. Following review by an independent adjudication committee, grade 1/2 interstitial lung disease thought to be related to MORAb-202 was identified in five (23%) patients. Complete response, partial response, and stable disease were observed in one, nine, and eight patients, respectively. The normalized predose serum FRα tended to be positively correlated with the maximum tumor shrinkage (R2 = 0.2379; P = 0.0291).

Conclusions::

The MTD of MORAb-202 was not reached. MORAb-202 demonstrated promising antitumor activity in FRα-positive solid tumors and was generally well-tolerated at the tested doses. Further investigations are required to establish appropriate dosage and clinical utility of MORAb-202.

2021-06-01·Cancer science

Antibody‐drug conjugate MORAb‐202 exhibits long‐lasting antitumor efficacy in TNBC PDx models

Article

作者: Moriyama, Tomoyuki ; Fernando, Shawn ; Cheng, Xin ; Wilson, Kerrianne ; Furuuchi, Keiji ; Rybinski, Katherine ; Drozdowski, Brian ; Milinichik, Andrew ; Albone, Earl ; Tanaka, Keigo ; Dula, Mary Lou ; Uenaka, Toshimitsu ; Soto, Allis ; Fulmer, James

Abstract:

The antibody‐drug conjugate (ADC) MORAb‐202, consisting of farletuzumab paired with a cathepsin B–cleavable linker and eribulin, targets folate receptor alpha (FRA), which is frequently overexpressed in various tumor types. MORAb‐202 was highly cytotoxic to FRA‐positive cells in vitro, with limited off‐target killing of FRA‐negative cells. Furthermore, MORAb‐202 showed a clear in vitro bystander cytotoxic effect in coculture with FRA‐positive/negative cells. In vivo antitumor efficacy studies of MORAb‐202 were conducted with a single administration of MORAb‐202 in triple‐negative breast cancer (TNBC) patient–derived xenograft (PDx) models expressing low and high levels of FRA. MORAb‐202 exhibited durable efficacy proportional to tumor FRA expression. Toxicology studies (Q3Wx2) in nonhuman primates suggested that the major observed toxicity of MORAb‐202 is hematologic toxicity. Overall, these findings support the concept that MORAb‐202 represents a promising investigational ADC for the treatment of TNBC patients.

项与 Farletuzumab Ecteribulin 相关的新闻（医药）

2024-11-29

·ioncology

除了HER2和Trop-2，乳腺癌ADC还有哪些潜在靶点

点击上方蓝字关注我们乳腺癌作为一种全球女性癌症相关死亡的主要原因，其治疗策略的创新和优化一直是医学研究的热点。近年来，抗体药物偶联物（ADC）在乳腺癌治疗领域取得了突破性进展，尤其是针对HER2和Trop-2的ADC。例如，德曲妥珠单抗（T-DXd）在HER2阳性和HER2低表达乳腺癌患者中显示出相较于传统治疗方案的显著疗效获益[1-2]；戈沙妥珠单抗（SG）在HR+/HER2-晚期乳腺癌以及晚期三阴性乳腺癌（TNBC）也取得了突破性研究进展[3-4]。然而，乳腺癌的异质性意味着单一靶点的ADC可能无法满足所有患者的治疗需求。因此，研究者们正在探索新的靶点，以期开发更广泛的新型ADC。Corti C等人总结了以下有潜力的乳腺癌ADC新靶点[5]。 Nectin-4 Nectin-4是一种细胞黏附分子，可在乳腺癌等多种肿瘤细胞中表达上调，通过PI3K-Akt和Wnt-β-catenin信号通路促进细胞增殖和转移。Nectin-4的过表达与肿瘤的侵袭性和转移潜力增加相关，使其成为ADC开发的一个有吸引力的靶点。例如，Enfortumab vedotin（EV）是首个针对Nectin-4的ADC，主要通过蛋白酶可裂解的连接子将载药抗微管剂MMAE递送至肿瘤细胞，该药物已在尿路上皮癌中显示出疗效获益。组织因子组织因子（Tissue factor，TF）是一种跨膜蛋白，也被称为血栓调节素或CD142。除了具有凝血作用外，TF还参与了肿瘤的多种生理和病理过程。TF可在多种肿瘤中的表达，特别是在乳腺癌、卵巢、前列腺、膀胱等，TF与肿瘤的侵袭性和不良预后相关。目前，已有靶向于TF的ADC报道，如Tisotumab vedotin（TV）是通过酶裂解连接子与微管蛋白抑制剂auristatin E结合的新型ADC。2期InnovaTV-204研究显示其在晚期宫颈癌有积极抗肿瘤活性。间皮素间皮素（Mesothelin）间皮素是一种糖基磷脂酰锚定的细胞表面蛋白，可能参与细胞黏附；尽管间皮素的表达仅限于胸膜的间皮细胞，包括心包膜、腹膜、角膜和结膜，但在所有癌症中，大约有高达30%存在过表达。间皮素表达的增加也与乳腺癌患者的总体生存率低有关，可能是因为异常的间皮素表达在促进转移中发挥了重要作用。目前报道的Anetumab ravtansine（AR）、RC88正是靶向于间皮素的新型ADC，在纳入包括TNBC在内的1/2期篮子试验中显示抗肿瘤活性。 LIV-1 LIV-1属于跨膜锌转运蛋白家族，其在乳腺癌中的表达似乎对雌激素水平敏感。LIV-1在乳腺癌中的表达可能与肿瘤的生长和转移有关，特别是在激素受体阳性的乳腺癌中，雌激素受体（ER）可诱导LIV-1表达上调。靶向于LIV-1的代表性ADC有Ladiratuzumab vedotin（LV），目前正在开展针对LIV1阳性的HR+/HER2-晚期乳腺癌和晚期TNBC患者的1期研究。 ROR1和ROR2 ROR1和ROR2是受体酪氨酸激酶样孤儿受体，它们在多种肿瘤中的高表达与不良预后相关，这些受体在乳腺癌中的表达可能与肿瘤的侵袭性和对治疗耐药性相关，尤其ROR1的表达是TNBC的潜在生物标志物，抑制ROR1可使TNBC干细胞向管腔化表型转变。NBE-002是靶向ROR1的ADC，其用于TNBC等晚期实体瘤的1/2期研究正在开展中。 HER3 HER3是HER家族的一员，其在多种癌症中的过表达与耐药性有关，HER3在乳腺癌中的表达可能与肿瘤对抗HER2靶向治疗的耐药性相关。Patritumab deruxtecan等靶向于HER3的新型ADC在乳腺癌领域已显示一定的抗肿瘤活性，对HER3高或低表达的HR+/HER2-晚期乳腺癌、HER3高表达的晚期TNBC、HER3高表达的HER2阳性晚期乳腺癌的ORR分别为30.1%、22.6%、42.9%。 Globo-H Globo-H是一种肿瘤相关碳水化合物抗原，在乳腺癌等多种上皮癌细胞类型中呈过表达状态，与肿瘤的侵袭性和转移潜力增加有关。Globo-H已被广泛研究并用于开发治疗性癌症疫苗，而靶向于Globo-H的新型ADC（如OBI-999）尚处于早期临床研究阶段。 FRα 叶酸受体α（FRα）是一种在转移性TNBC中表达的糖基磷脂酰膜蛋白，与不良预后相关；大约有70%～86%的转移性TNBC表达FRα，而正常组织通常不表达。MORAb-202是靶向FRα的新型ADC，首次人体1期试验探讨了该药物的安全性和耐受性。 B7-H4 B7-H4是一种免疫检查点配体，其在多种肿瘤中的高表达与不良预后相关；B7-H4在乳腺癌中的表达可能与肿瘤的免疫逃逸机制相关。靶向B7-H4的代表性新型ADC有SGN-B7H4V、MORAb-202等。 △正在开展临床试验的新靶点ADC 乳腺癌治疗的研究正在持续推进，层出不穷的新型ADCs研发为患者带来了新的希望。除了HER2和Trop-2以外，靶向于Nectin-4、TF、Mesothelin、LIV-1、ROR1、ROR2、HER3、Globo-H、FRα和B7-H4等新靶点的ADC，正在成为研究的焦点。这些靶点的ADC在临床前和临床研究中显示出潜力，预示着乳腺癌治疗的新方向。期待这些ADC能够为乳腺癌患者带来更有效的治疗选择，进一步改变乳腺癌的治疗格局。声明：材料由阿斯利康支持，仅供医疗卫生专业人士参考 CN-148470 Expiration Date: 2025-11-27 ▌参考文献： [1]Cortés J, Kim SB, Chung WP, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022;386(12):1143-1154. doi:10.1056/NEJMoa2115022 [2]Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9-20. doi:10.1056/NEJMoa2203690 [3]Bardia A, Rugo HS, Tolaney SM, et al. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol. 2024;42(15):1738-1744. doi:10.1200/JCO.23.01409 [4]Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10411):1423-1433. doi:10.1016/S0140-6736(23)01245-X [5]Corti C, Boscolo Bielo L, Schianca AC, Salimbeni BT, Criscitiello C, Curigliano G. Future potential targets of antibody-drug conjugates in breast cancer. Breast. 2023;69:312-322. doi:10.1016/j.breast.2023.03.007 （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

抗体药物偶联物临床结果临床2期突破性疗法

2024-11-18

·Pharmaceutical Technology

AbbVie’s Elahere wins European approval for certain ovarian cancers

GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: Skorzewiak via Shutterstock. The European Commission (EC) has granted marketing authorisation to AbbVie ’s Elahere (mirvetuximab soravtansine) for the treatment of folate receptor-alpha (FRα) platinum-resistant ovarian cancer, a decade since the approval of the latest treatment. Antibody-drug conjugate (ADC) Elahere has received European approval for the treatment of adult patients with FRα positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancers. The therapy is authorised for patients who have undergone one to three prior systemic treatment regimens. Approximately 35%-40% of ovarian cancer patients express FRα, a biomarker specifically targeted by Elahere. By delivering the cytotoxic agent DM4 directly to cancer cells while sparing healthy tissue, the treatment aims to minimise off-target effects and reduce toxicity compared to traditional chemotherapy. Elahere’s approval is supported by data from the Phase III MIRASOL trial (NCT04209855), which enrolled 453 patients with FRα-positive platinum-resistant ovarian cancer. The treatment demonstrated a significant and clinically meaningful 35% reduction in the risk of disease progression or death, compared to standard chemotherapy. Patients treated with Elahere had a median progression-free survival (PFS) of 5.6 months, slightly longer than the four months observed in patients who received standard chemotherapy. Moreover, patients in the Elahere arm showed a median overall survival (OS) of 16.5 months while those in the investigator’s choice chemotherapy arm had a median OS of 12.8 months. The approval of Elahere addresses an unmet need for patients with platinum-resistant ovarian cancer. “It’s been ten years since a new treatment for platinum-resistant ovarian cancer was approved in the EU, and now oncologists have an effective, new, targeted treatment option for these patients,” said Toon Van Gorp, professor of gynaecological oncology at the University of Leuven. AbbVie inherited Elahere as part of a $10.1bn acquisition of ImmunoGen . The drug received accelerated approval by the US Food and Drug Administration (FDA) in November 2022 and was granted full FDA approval in the US in March 2024. GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. As the first FRα-targeted ADC approved in the EU, Elahere represents a competitive advantage for AbbVie in the ovarian cancer treatment landscape. GlobalData is the parent company of Pharmaceutical Technology. Elahere faces competition from Bristol Myers Squibb and Eisai ’s ADC farletuzumab ecteribulin, which is currently being investigated in Phase II trials. However, Elahere holds the first-to-market advantage. The drug is currently being investigated in three other ovarian cancer trials, in combination with Roche’s Avastin (bevacizumab) in the Phase III GLORIOSA study (NCT05445778), as a monotherapy in the Phase II PICCOLO study (NCT05041257), and with carboplatin in another Phase II trial (NCT05456685).

上市批准临床3期临床2期临床结果抗体药物偶联物

2024-10-04

·医药笔记

Genmab/普方生物：FRα ADC启动三期临床

2024年10月1日，Genmab在Clinicaltrials.gov网站上注册了FRα ADC新药Rina-S的三期临床试验。该三期临床计划入组530例铂类化疗抵抗晚期卵巢癌患者，与化疗头对头对照，预计2027年2月初步完成。 Rina-S由普方生物研发，此前的研发代码为PRO1184，Fc引入LALA改造，payload采用自主研发的TOPO1抑制剂LD038。2024年4月，Genmab以18亿美元的价格收购普方生物。 Immunogen的Elahere为全球首款上市的FRα ADC，上市后放量迅速，今年上半年销售额1.92亿美元。2023年11月，艾伯维以101亿美元价格收购Immunogen。Genmab/普方生物紧随其后进入三期临床，礼来则刚刚启动一期临床。此外，百时美施贵宝已退回卫材引进的Farletuzumab ecteribulin。内容来源于网络，如有侵权，请联系删除。

并购抗体药物偶联物

100 项与 Farletuzumab Ecteribulin 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
铂耐药性输卵管癌	临床2期	美国	Eisai, Inc.	2023-02-01
铂耐药性输卵管癌	临床2期	美国	Bristol Myers Squibb Co.	2023-02-01
铂耐药性输卵管癌	临床2期	日本	Eisai, Inc.	2023-02-01
铂耐药性输卵管癌	临床2期	日本	Bristol Myers Squibb Co.	2023-02-01
铂耐药性输卵管癌	临床2期	澳大利亚	Bristol Myers Squibb Co.	2023-02-01
铂耐药性输卵管癌	临床2期	澳大利亚	Eisai, Inc.	2023-02-01
铂耐药性输卵管癌	临床2期	比利时	Eisai, Inc.	2023-02-01
铂耐药性输卵管癌	临床2期	比利时	Bristol Myers Squibb Co.	2023-02-01
铂耐药性输卵管癌	临床2期	智利	Bristol Myers Squibb Co.	2023-02-01
铂耐药性输卵管癌	临床2期	智利	Eisai, Inc.	2023-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03386942 (ESMO_GCC2023)	临床1期	卵巢癌	82	MORAb-202 0.9 mg/kg	繭醖觸壓繭鑰蓋壓淵獵(網選醖窪夢艱餘繭網構) = Translocation of HMGB1 and enhanced HSP90 production as ICD biomarkers were observed in triplicate tumor samples treated with MORAb-202 and eribulin 壓壓簾製鑰衊窪餘憲蓋 (夢獵餘鑰鏇廠鏇餘範蓋 ) 更多	-	2023-02-23
				MORAb-202 1.2 mg/kg
2022-RA-680-ESGO (ESGO2022)	临床1期	铂耐药性卵巢癌 FRÎ±-expression levels	-	MORAb-202 0.9 mg/kg	憲願廠遞繭鹽願築鑰壓(窪淵鬱積顧衊餘糧蓋遞) = 醖鬱選蓋獵簾顧築膚選願膚願壓製糧鑰糧繭繭 (衊襯蓋壓範夢餘鑰範製 )	-	2022-10-20
				MORAb-202 1.2 mg/kg	憲願廠遞繭鹽願築鑰壓(窪淵鬱積顧衊餘糧蓋遞) = 衊積齋獵淵遞鬱廠鑰窪願膚願壓製糧鑰糧繭繭 (衊襯蓋壓範夢餘鑰範製 )
NCT03386942 (ASCO2022)	临床1期	铂耐药性卵巢癌	45	MORAb-202 0.9 mg/kg	糧遞鹽繭願繭艱壓築簾(襯鑰構簾鑰齋壓遞繭齋) = 醖鏇廠醖艱鑰壓獵顧遞糧蓋窪壓網鹽蓋膚窪淵 (遞顧衊製鏇範鑰襯憲壓 )	-	2022-06-02
				MORAb-202 1.2 mg/kg	糧遞鹽繭願繭艱壓築簾(襯鑰構簾鑰齋壓遞繭齋) = 餘簾糧鑰鹹繭鏇選製餘糧蓋窪壓網鹽蓋膚窪淵 (遞顧衊製鏇範鑰襯憲壓 )
NCT03386942 (ASCO2022)	临床1期	实体瘤	82	MORAb-202 BSA-based dosing (33 mg/m2)	製範窪蓋憲襯鏇範繭繭(網鑰糧獵鏇選淵簾鏇簾) = rates of all-grade interstitial lung disease (ILD), an adverse event of interest, were lower at the 0.9 mg/kg dose vs the 1.2 mg/kg dose 鹹簾膚繭遞積築蓋鬱廠 (壓蓋膚鏇淵餘糧積壓醖 ) 更多	-	2022-06-02
				MORAb-202 BW-based dosing (0.9 mg/kg)
NCT03386942 (pubmed \| Clin Cancer Res) 人工标引	临床1期	实体瘤 Folate Receptor-α-Positive	22	MORAb-202	願蓋鹹繭糧觸鹹積範餘(廠製選積鹹餘憲選壓淵) = 壓觸憲鑰壓簾憲鏇憲範選顧襯憲繭壓壓齋製繭 (簾鑰鬱膚淵壓淵顧糧範 ) 更多	积极	2021-07-15
NCT03386942 (ASCO2019)	临床1期	实体瘤	16	MORAb-202	構鹹遞淵鹹構積窪鹽襯(糧鏇觸選顧淵鏇夢鑰襯) = The most common TEAEs were leukopenia and neutropenia (50% each) 鬱齋醖鏇醖糧淵憲遞壓 (繭選窪窪廠鏇鹽膚鑰廠 )	积极	2019-05-26
NCT00738699 (FAR-122, CTgov)	临床2期	复发性卵巢癌	415	MORAb-003 (Farletuzumab)+Paclitaxel (MORAb-003 (Farletuzumab) Plus Paclitaxel)	夢簾築鏇艱壓膚餘廠壓(積窪襯簾顧鏇製糧襯壓) = 壓鹹願膚製襯壓鹽膚鑰窪壓鹽鹹製醖範衊鏇顧 (糧廠網壓構遞築選壓積, 觸顧遞積鑰齋積積餘衊 ~ 築艱壓鑰襯齋廠鏇鬱廠) 更多	-	2017-03-30
				Placebo+Paclitaxel (Placebo (Normal Saline) Plus Paclitaxel)	夢簾築鏇艱壓膚餘廠壓(積窪襯簾顧鏇製糧襯壓) = 築觸淵網齋顧醖選艱窪窪壓鹽鹹製醖範衊鏇顧 (糧廠網壓構遞築選壓積, 築齋膚選襯糧醖觸餘願 ~ 憲選憲構齋鏇鏇積餘鹹) 更多